In CHIP, CpG sites that were negatively associated with DNMT3A mutations were underrepresented among the 2741 TET2-associated hypermethylated CpG sites (48% compared to 54% of other sites, P = 6 × 10−10, χ2 test Supplementary Fig. 16), but in AML the 2000 TET2-associated hypermethylated sites were enriched for hypomethylation in DNMT3A-mutated tumors (P < 1 × 10−16, χ2 test). This evidence concerns the gene TET2 and acute myeloid leukemia.